Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

587P - Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide)

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Prostate Cancer

Presenters

Alicia Morgans

Citation

Annals of Oncology (2021) 32 (suppl_5): S626-S677. 10.1016/annonc/annonc702

Authors

A.K. Morgans1, T.E. Hutson2, A.K. Guan3, D. Garcia3, A. Zhou3, E.J. Drea4, N.J. Vogelzang5

Author affiliations

  • 1 Medicine, Dana Farber Cancer Institute, 60611 - Boston/US
  • 2 Gu Oncology, Texas Oncology - Baylor Sammons Cancer Center, 75246 - Dallas/US
  • 3 Biomedical Communications, CRG-EVERSANA, L7N 3H8 - Burlington/CA
  • 4 Oncology, Sanofi Genzyme, 02142 - Cambridge/US
  • 5 Comprehensive Cancer Centers Of Nevada, US Oncology Research, 80525 - Las Vegas/US
More

Abstract 587P

Background

Cabazitaxel has significantly improved clinical outcomes compared to a 2nd ARTA in mCRPC pts who previously received docetaxel and the alternative ARTA. We sought to determine resource costs avoided with cabazitaxel in 3L treatment vs a second ARTA in mCRPC pts.

Methods

Inputs were derived from CARD data, medical literature, and estimates (by 3 GU oncologists, AM,TH,NJV) of typical clinical care patterns (TCCP). An Excel model was created to assess data at 6, 12, 18, and 24 months for pts similar to CARD pts. Outcomes included number of pts without (w/o) progression and still alive, hospitalization and ICU days, and costs of management of symptomatic skeletal events (SSEs), adverse events (AEs), and end-of-life care. The cost impact was modeled for a cohort of mCRPC pts receiving cabazitaxel vs a same-size cohort receiving ARTA in 3L, costs in 2020 US$.

Results

Cabazitaxel use in 100 pts was estimated to result in 9 more pts w/o progression and 17 less deaths vs the use of a 2nd ARTA over an 18-month period (Table). The costs of SSEs, AEs, and end-of-life care were $498,909, $276,198, and $808,785, respectively, for cabazitaxel pts, and $627,569, $251,124, and $1,028,294, respectively, for ARTA pts. Cabazitaxel was associated with 58 fewer hospitalization days and 2 fewer ICU days and was estimated to avoid $323,095 in costs, driven by SSEs and end-of-life care.

Conclusions

The use of cabazitaxel as a 3L treatment after docetaxel and ARTA in mCRPC pts is predicted to result in clinical benefits (longer rPFS, OS) and fewer hospitalization and ICU days. Compared to a 2nd ARTA, cabazitaxel was estimated to be associated with a 21% reduction in both SSE and end-of-life care costs and a 10% increase in AE costs, for an overall decrease of 17% in costs. Table: 587P

Outcomes at 18 months

Cabazitaxel ARTA Difference
rPFS (n) 15 6 9
OS (n) 38 21 17
Hospitalization days 260 318 -58
ICU days 6 8 -2
Resource Utilization Costs (2020 USD) 1,583,892 1,906,987 -323,095
SSEs 498,909 627,569 -128,660
AEs 276,198 251,124 25,074
End-of-Life Care 808,785 1,028,294 -219,509

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Sanofi-Genzyme.

Funding

Sanofi-Genzyme.

Disclosure

A.K. Morgans: Financial Interests, Institutional, Advisory Board: Astellas; Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: Bayer; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Advisory Board: Sanofi; Financial Interests, Institutional, Advisory Board: Seattle Genetics; Financial Interests, Institutional, Advisory Board: Genentech. T.E. Hutson: Financial Interests, Institutional, Advisory Role: Astellas; Financial Interests, Institutional, Advisory Board: Aveo; Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Board: Eisai; Financial Interests, Institutional, Advisory Board: EMD Serono; Financial Interests, Institutional, Advisory Board: Exelixis; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Advisory Board: Merck; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: Pfizer. E.J. Drea: Financial Interests, Personal, Stocks/Shares, Employed by Sanofi: Sanofi-Genzyme. N.J. Vogelzang: Financial Interests, Institutional, Advisory Board: Aveo; Financial Interests, Institutional, Advisory Board: Celgene; Financial Interests, Institutional, Advisory Board: Dendreon; Financial Interests, Institutional, Advisory Board: Exelixis; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: OncoGene; Financial Interests, Institutional, Advisory Board: Veridex; Financial Interests, Institutional, Invited Speaker: Caris Life Scinecnes; Financial Interests, Institutional, Invited Speaker: Eli Lilly; Financial Interests, Institutional, Invited Speaker: Novartis; Financial Interests, Institutional, Invited Speaker: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.